Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
靶向肿瘤衍生的可溶性 NKG2D 配体 sMIC 的抗体可对 CD8 T 细胞进行双重共刺激,并使 sMIC+ 肿瘤对 PD1/PD-L1 阻断疗法产生反应
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.3
doi:10.1186/s40425-019-0693-y
Jinyu Zhang, Pablo Saenz-Lopez Larrocha, Bin Zhang, Derek Wainwright, Payal Dhar, Jennifer D Wu